Skip to Content

Join the 'Plaque Psoriasis' group to help and get support from people like you.

Plaque Psoriasis News

FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis

Posted 13 Nov 2016 by Drugs.com

THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. "As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a need for FDA approved systemic therapies in the pediatric setting. Until now, no biologics — which are effective in treating adults with moderate-to-severe plaque psoriasis — had been approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in children," said Randy Beranek, president and chief executive officer of the National Psoriasis Foundation. "This new approval is an important dev ... Read more

Related support groups: Psoriasis, Enbrel, Plaque Psoriasis, Etanercept

Health Tip: Keep Psoriatic Arthritis Fatigue in Check

Posted 11 Nov 2016 by Drugs.com

-- Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have moderate-to-severe fatigue. The Foundation suggests: Exercise regularly to help ease pain and boost energy. Eat a nutritious, well-balanced diet. Get plenty of sleep. If you have a sleep disorder, seek treatment. Prioritize your to-dos, and pace yourself throughout the week. Read more

Related support groups: Fatigue, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

Amjevita OK'd to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis and juvenile idiopathic arthritis, the FDA said in a news release. Biological drugs are generally derived from a living organism and can come from many sources, including humans, animals, microorganisms or yeast, the FDA said. A biosimilar drug is a biological product that's sanctioned after its maker proves it is "highly similar" to an already-approved biologic drug. The manufacturer of the biosimilar drug must prove that the product has "no clinically meaningful differences" in safety, purity ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Ulcerative Colitis - Active, Plaque Psoriasis, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Amjevita

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis. Amjevita is also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of age and older. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. “This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new fr ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Adalimumab, Amjevita

FDA Approves Erelzi (etanercept-szzs), a Biosimilar to Enbrel

Posted 1 Sep 2016 by Drugs.com

August 30, 2016 – The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. Erelzi is administered by injection for the treatment of: moderate to severe rheumatoid arthritis, either as a standalone therapy or in combination with methotrexate (MTX); moderate to severe polyarticular juvenile idiopathic arthritis in patients ages two and older; active psoriatic arthritis, including use in combination with MTX in psoriatic arthritis patients who do not respond adequately to MTX alone; active ankylosing spondylitis (an arthritis that affects the spine); and chronic moderate to severe plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy. Health care professionals should review the prescribing ... Read more

Related support groups: Rheumatoid Arthritis, Enbrel, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Juvenile Idiopathic Arthritis, Etanercept, Erelzi

Treating Psoriasis May Reduce Risk for Other Ills

Posted 29 Jul 2016 by Drugs.com

FRIDAY, July 29, 2016 – Treating the skin disease psoriasis might reduce your risk for other health problems as well, a dermatology expert says. About 7.5 million people in the United States have the chronic skin disease. The inflammatory effects of psoriasis can affect the entire body, said Dr. Jashin Wu, director of dermatology research at Kaiser Permanente Los Angeles Medical Center. "People with psoriasis, particularly those with more severe disease, have an increased risk for a variety of other health problems, including obesity, diabetes, high blood pressure, high cholesterol, stroke and heart attack," he said in an American Academy of Dermatology news release. Psoriasis is characterized by red, raised patches of skin, or plaques, covered with silvery-white scales. It's also marked by itching, burning or soreness of the skin. It is not contagious. "Psoriasis patients, even those ... Read more

Related support groups: High Blood Pressure, Diabetes, Type 2, Obesity, Hypertension, High Cholesterol, Heart Attack, Psoriasis, Inflammatory Conditions, Insulin Resistance, Pre-Diabetes, Myocardial Infarction, Plaque Psoriasis, Diabetes Mellitus, Abnormal Glucose Tolerance, Myocardial Infarction - Prophylaxis, Psoriatic Arthropathy

Health Tip: Coping With Scalp Psoriasis

Posted 24 Jun 2016 by Drugs.com

-- If dry, itchy scalp psoriasis is bothering you, there are things you can do to help bring it under control. The American Academy of Dermatology advises: Avoid scratching your scalp. Treat the psoriasis to minimize the itching. Be gentle when shampooing your hair; don't rub or scrub. Gently remove scales from the scalp, taking care not to pick them off. Talk to your dermatologist about a skin softener. Find healthy ways to manage stress. Read more

Related support groups: Psoriasis, Plaque Psoriasis

New Psoriasis Drug Works Longer Term, Too

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – A new drug that has shown "unprecedented" effects on the skin condition psoriasis seems to work well in the longer term, too, researchers report. The drug, called ixekizumab (Taltz), was approved in March by the U.S. Food and Drug Administration. That came after initial trials showed that over 12 weeks, the drug soundly beat standard medication for moderate-to-severe psoriasis. The new findings show the benefits are still there after 60 weeks. At that point, about 80 percent of patients were seeing at least a 75 percent improvement in their skin symptoms, the researchers said. So far, ixekizumab has shown "unprecedented efficacy" against more severe cases of psoriasis, said Dr. Joel Gelfand, a dermatologist who wasn't involved in the research. The drug, given by injection, targets an inflammatory protein called IL-17, said Gelfand, who directs the Psoriasis ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Taltz, Psoriatic Arthropathy

Psoriasis Tied to Obesity, Type 2 Diabetes

Posted 27 Apr 2016 by Drugs.com

WEDNESDAY, April 27, 2016 – The chronic skin disease psoriasis may be linked to excess weight and type 2 diabetes, results of a new study suggest. Danish researchers found that people with type 2 diabetes had more than 50 percent greater odds of having psoriasis compared to people without diabetes. The study also found that the rate of psoriasis went up with increasing weight. For example, obese people with a body mass index (BMI) over 35 had almost double the odds of psoriasis than normal weight people did. BMI is a body fat measurement based on height and weight. A BMI of 30 or over is considered obese. Exactly how these conditions might be connected isn't clear, but the study authors suggested that genetics, smoking, drinking alcohol, or inflammation might play a role. "Psoriasis is a complex disorder," said lead researcher Dr. Ann Sophie Lonnberg, of the University of Copenhagen. ... Read more

Related support groups: Diabetes, Type 2, Obesity, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

Psoriasis May Raise Risk for Aneurysms in Abdomen: Study

Posted 15 Apr 2016 by Drugs.com

THURSDAY, April 14, 2016 – Psoriasis patients may face a higher risk of an abdominal aortic aneurysm, though the overall odds of experiencing this potentially deadly blood vessel rupture are small, new research shows. The Danish scientists also found that the more severe the psoriasis – a chronic autoimmune condition characterized by scaly, red patches of skin – the more likely a person will develop an abdominal aortic aneurysm. They believe the two conditions share overlapping inflammatory processes in the body. "The association between [abdominal aortic aneurysm] and psoriasis has not been examined before, but we are not surprised by seeing a heightened risk in our study," said lead researcher Dr. Usman Khalid, a fellow in the department of cardiology at Herlev and Gentofte Hospital in Hellerup, Denmark. "Our results add to the evidence that there is an increased risk of various ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Aortic Aneurysm

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Ulcerative Colitis - Active, Plaque Psoriasis, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

Posted 7 Apr 2016 by Drugs.com

April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab), which was originally licensed in 1998. Inflectra is approved and can be prescribed by a health care professional for the treatment of: adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy; adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy; patients with moderately to severely active rheumatoid arthritis in combination with methotrexate; patients with active ankylosing spondylitis (arthritis of ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Infliximab, Inflectra

FDA Approves Taltz (ixekizumab) for Plaque Psoriasis

Posted 23 Mar 2016 by Drugs.com

March 22, 2016 – The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales. “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Taltz’s active ingredient is an antibody (ixekizumab) that bi ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Taltz, Ixekizumab

Safe Treatments Available for Expectant Moms' Skin Conditions

Posted 4 Mar 2016 by Drugs.com

FRIDAY, March 4, 2016 – There are a number of safe and effective ways to treat chronic skin conditions in pregnant women, a dermatologist says. "If there is a way to manage your skin condition without medication during pregnancy, that is the preferred option," said Dr. Jenny Eileen Murase, an assistant clinical professor of dermatology at the University of California, San Francisco. "If you have a condition that does require medication, however, a board-certified dermatologist can help you identify a treatment that's safe for both you and your baby," she added in an American Academy of Dermatology news release. The release was timed to coincide with the academy's annual meeting, which starts Friday in Washington, D.C. Eczema is the most common rash dermatologists see in pregnancy, Murase said. "Expectant mothers often see their existing eczema get worse or have a flare for the first ... Read more

Related support groups: Clindamycin, Psoriasis, Eczema, Retin-A, Epiduo, Benzoyl Peroxide, Plaque Psoriasis, Acne Treatment, Cleocin, Adapalene, Salicylic Acid, Finacea, Differin, Aczone, Compound W, Duac, Benzaclin, Duofilm, Ziana, Atralin

Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray

Posted 10 Feb 2016 by Drugs.com

HYDERABAD, India & PRINCETON, N.J., February 07, 2016 --(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05% from the U.S. Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planned for the coming quarter. Commenting on the approval, G V Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories said, “The FDA approval of Sernivo Spray is a significant milestone for Promius, as it validates our committed efforts and resources to developing differentiated dermatology products from concept to commercial launch. We are delighted to receive a first round FDA appro ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Sernivo

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Psoriasis

Related Drug Support Groups

Humira, methylprednisolone, Enbrel, Remicade, dexamethasone, Otezla, hydroxyurea, Cosentyx, Dovonex, view more... infliximab, Taclonex, adalimumab, etanercept, calcipotriene, apremilast, secukinumab, Enstilar, Taltz, Taclonex Scalp, Erelzi, Amjevita, Inflectra, Amevive, alefacept, Sernivo, Dovobet, Raptiva, ixekizumab, efalizumab, Sorilux, Calcitrene, betamethasone / calcipotriene